CoVFlu One Step RT-PCR Kit

Product Overview

SARS-CoV-2, Influenza A and B, and RSV are among the most clinically significant respiratory pathogens in circulation today. They share overlapping symptoms, co-circulate seasonally, and can co-infect the same patient, making individual pathogen testing an inefficient and incomplete approach to respiratory diagnostics. Each virus poses distinct risks: COVID-19 can cause severe systemic illness, influenza is a leading cause of seasonal mortality, and RSV is a major threat to infants, young children, and older adults.

The CoVFlu One Step RT-PCR Kit from Genes2Me delivers simultaneous detection and differentiation of all four pathogens in a single assay. It targets highly conserved viral genomic regions to ensure specificity across variants, providing comprehensive respiratory surveillance from a single nasopharyngeal or oropharyngeal swab collected in VTM

Targets:
SARS-CoV-2, Influenza A, Influenza B, RSV
Technology:
Multiplex One-Step Real-Time RT-PCR
Detection:
Qualitative (Detected / Not Detected)
Sample Type:
Nasopharyngeal & Oropharyngeal Swabs in VTM
Certification:
CE-IVD
CoVFlu One

Genes2Me is a CE Marked molecular diagnostics company trusted by clinical laboratories across global markets. The CoVFlu One Step RT-PCR Kit meets European conformity standards for in vitro diagnostic devices, validated to international benchmarks for accuracy, reliability, and safety.

How the Assay Works

The CoVFlu kit uses a one-step reverse transcription and real-time PCR amplification design, targeting highly conserved genomic regions of each pathogen: RdRp and N genes for SARS-CoV-2, M1/M2 for Influenza A, NEP for Influenza B, and NS1 for RSV. Human RNaseP serves as an internal control, monitoring PCR inhibition and validating extraction and amplification in every run. Positive and negative controls are included to ensure the integrity of each run and guard against contamination.

Why Multiplex Testing Matters

SARS-CoV-2, influenza, and RSV co-circulate during respiratory seasons, and their symptoms are clinically indistinguishable without laboratory confirmation. Running four separate tests increases cost, delays results, and consumes sample volume. A single multiplex assay with a built-in internal control detects all four pathogens simultaneously, reduces the risk of false negatives, and enables faster, more informed treatment decisions. This is especially critical during peak respiratory seasons when diagnostic demand is highest.

Sample Type & Reporting Output

Sample Type:
Nasopharyngeal and oropharyngeal swabs in Viral Transport Media (VTM)
Reporting Output:
Qualitative detection of SARS-CoV-2, Influenza A, Influenza B, RSV (Detected / Not Detected)
Targets Detected:
SARS-CoV-2, Influenza A, Influenza B, RSV

Key Features & Benefits

Simultaneous detection of four respiratory pathogens

A single assay identifies SARS-CoV-2, Influenza A, Influenza B, and RSV, reducing turnaround time and the need for multiple individual tests.

Highly conserved genomic targets

Targets RdRp and N genes of SARS-CoV-2, M1/M2 of Influenza A, NEP of Influenza B, and NS1 of RSV, ensuring high specificity across viral variants.

RNaseP internal control in every run

Monitors PCR inhibition and validates extraction and amplification, effectively preventing false-negative results.

All reagents included

Primer-probe mixes, master mix, positive control templates, and RNase/DNase-free water are all supplied, supporting streamlined and contamination-free workflows.

Compatible with multiple leading PCR platforms

Validated on RapiCycler 96, Bio-Rad CFX96, QuantStudio 5, and LightCycler 480. No new capital expenditure required.

Positive and negative controls included

Both controls are supplied in every kit, ensuring the integrity of each run and delivering confidence in diagnostic decisions.

Applications

  • Clinical & Hospital Laboratories: Enables comprehensive respiratory pathogen detection in a single assay, supporting faster differential diagnosis and more targeted clinical management of COVID-19, influenza, and RSV.
  • Paediatric & Neonatal Care: Critical for young children and infants, where RSV and influenza can cause severe respiratory complications and where co-infections with SARS-CoV-2 require rapid differentiation.
  • Outbreak Surveillance: Supports real-time monitoring of co-circulating respiratory viruses in hospitals, care homes, and community settings, enabling faster public health responses.
  • Immunocompromised Patients: Essential multiplex screening for transplant recipients, oncology patients, and those on immunosuppressive therapy, where any of the four targeted pathogens can cause life-threatening illness.
  • Travel & Occupational Health: Efficient, all-in-one screening in international travel clinics and occupational health programmes where multiple respiratory pathogens circulate simultaneously.

Analytical Performance

  • High analytical sensitivity and specificity across all four targets
  • Ct cut-off of 35 or below for positive detection across SARS-CoV-2, Influenza A, Influenza B, and RSV
  • RNaseP internal control monitors PCR inhibition and prevents false-negative results
  • Positive and negative controls included for full assay integrity validation

Ordering Information

Commercial Name Old Cat No. New Cat No. Pack Size
CoVFlu One Step RT-PCR Kit G2M272721R 50 Tests

Product Enquiry Form

Other Products

Rapi-Q Series
Rapi-Q

Rapid and Compact Point-of-care RT-PCR Testing Solution.

Rapi-X96
RAPiCycler-96

Real time PCR system to process 96 samples.
TRapi-X96
Rapi-X16

Compact Nucleic Acid Extraction System Ideal for Point-of-Care Testing

Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.

© 2025 Genes2me. All rights reserved.